Naringin reduces body weight, plasma lipids and increases adiponectin levels in patients with dyslipidemia.

Abstract

Naringin is a citrus-flavonoid which has been shown to have positive metabolic and anti-inflammatory effects. For this reason, we believe it would be interesting to study the effects of Naringin administration on body weight, BMI, lipid profile and adiponectin levels in patients with dyslipidemia, especially considering that dyslipidemias along with obesity and subsequent cardiometabolic complications are some of the most important public health issues plaguing our society today. A double-blind, randomized clinical trial was conducted in a group of 28 adult patients previously diagnosed with dyslipidemia who attended the Institute of Experimental and Clinical Therapeutics. Patients were divided into two groups; the first group (n=14) received 450mg of naringin every 24hours, in the mornings, while the second group (n=14) was given a homologated placebo over the course of a 90-day period. Significant differences were observed in naringin group compared to the placebo group in terms of decreased BMI (30.6±3.19 vs 33.3±3.23kg/m2; p=0.03), total cholesterol (182±20.2 vs 245±24.1mg/dl; p<0.01), LDL cholesterol (100±17.5 vs 125±38.3mg/dl; p=0.03) and an increase in adiponectin levels (0.82±0.25 vs 0.59±0.19μg/ml; p=0.01). Our results support the use of Naringin as a potential therapeutic agent which could play an important role in the management of metabolic disorders.